Skip to main content

Table 1 Distribution of patients from stages 2-4 into stages A-D and substages C1-D3

From: Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial

  GOLD 2 GOLD 3 GOLD 4
  n = 2611 (46% of total) n = 2529 (45% of total) n = 490 (9% of total)
A 356 (14% of GOLD2) - -
B 1421 (54%) - -
C 89 (3%) 195 (8%) 12 (2%)
D 745 (29%) 2334 (92%) 478 (98%)
C1 * - 147 (6%) 6 (1%)
C2 * 89 (3%) - -
C3 * - 48 (2%) 6 (1%)
D1 *   1317 (52%) 246 (50%)
D2 * 745 (15%)   -
D3 *   1017 (40%) 232 (47%)
  1. * C1/D1, high risk is based on FEV1<50% only; C2/D2, based on history of frequent exacerbations only; C3/D3, based on both.